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Abstract
Recent molecular studies provide evidence for a significant transcriptional plasticity of tumor cell subpopulations that
facilitate an active contribution to tumor vasculature. This feature is accompanied by morphological changes both in vitro
and in vivo. Herein, we investigated the morphological plasticity of tumor cells with special focus on vasculogenic mimicry
and neovascularisation in human melanoma and mouse xenografts of human melanoma cell lines. In melanoma xenograft
experiments, different vessel markers and green fluorescent protein expression were used to show how melanoma cells
contribute to neovascularization. Additionally, we analyzed neovascularization in 49 primary melanomas and 175 melanoma
metastases using immunostaining for blood (CD34) and lymphatic (D2–40) vessel-specific markers. We found significantly
more lymphatic vessels in primary melanomas than in melanoma metastases (p,0.0001). In contrast to the near absence of
lymphatic vessels within metastases, we found extensive blood micro-neovascularization. Blood micro-neovascularization
was absent in micro metastases (less than 2 mm). A significant inverse correlation between Glut-1 expression (implying local
hypoxia) and the presence of microvessels indicates their functional activity as blood vessels (p,0.0001). We suggest that
the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically
contribute to blood vessel formation.
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Introduction
Melanoma is a highly aggressive neoplasm. Even very thin
primary tumors (Breslow tumor thickness ,1 mm) may seed
metastases and precipitate rapid death [1,2]. Several cancer
studies, including melanoma, have identified primary tumor
lymphangiogenesis and its predictive relevance for lymph node
metastasis [3,4,5,6]. Interestingly, animal tumor models for
melanoma and breast cancer have revealed vasculature reorgani-
sation in regional lymph nodes prior to invasion by metastatic
cancer cells [7,8,9,10].
The introduction of high through put assays such as gene
expression arrays have offered new tools for cancer classifications
including melanoma. [11]. Recently, we have demonstrated two
opposing gene expression profiles in melanoma short term cell
cultures associated with proliferative or invasive cell phenotypes
and provided evidence for phenotype switching favouring disease
progression [12,13]. This transcriptional plasticity is accompanied
by morphological changes in vitro, and involves many factors
governing angiogenesis. In 1999, Maniotis and co-workers
introduced the concept of vasculogenic mimicry (VM) in
melanoma [14]. He defined VM as melanoma cells with
endothelial-like morphology embedded in a PAS and collagen
IV positive extracellular matrix. The matrix with endothelial-like
melanoma cells forms loops or networks which may be solid or
hollow. VMs have been seen in additional malignant tumor types
including breast, liver, prostate and other cancers [15,16,17,18].
The presence of VMs have been associated with a poor clinical
outcome [14,19,20,21]. Furthermore, mosaic blood vessels in
which both endothelial cells and tumor cells form the luminal
surface have been described for both melanoma and colon cancer
[22,23,24]. Most recently, sophisticated investigations have shown
that tumor cells directly participate in blood vessel formation
[25,26].
In the present study we investigated melanoma metastases for
neovascularization in both human biopsies and mouse xenografts
of human melanoma cell lines. We found VMs and a tremendous
blood micro-neovascularization in human biopsies as well as in
xenografts. In the mouse xenografts of human melanoma cell lines
we showed melanoma cell participation in capillary formation.
Materials and Methods
Tissue microarray analysis
Immunohistochemistry was performed on three different tissue
microarrays (TMAs) representing a total of 49 primary melanomas
and 127 melanoma metastasis. The metastasis array included 21
lymph node and 106 organ metastases. Construction of TMAs was
performed as previously described [27]. Furthermore, in order to
avoid sampling error immunohistochemistry was performed on
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Approval for the use of melanoma TMAs and melanoma
metastases was obtained from the official ethical authorities of
the Canton Zurich. The consent statement was written (StV 16-
2007, permission submitted in the supplement).
Immunohistochemistry
Immunohistochemical stainings on TMAs and melanoma
metastases were performed using an automated immunostainer
(Ventana Medical Systems, Tucson, AZ, USA), utilizing the
antibodies anti-D2–40 (Dako A/S, clone D2–40, dilution 1:50,
pretreatment: CC1-buffer for 90 min./98uC), anti-CD34 (Novo-
castra, NCL-END, dilution 1:60, w/o pre-treatment), detection
was performed with Ultra View-HRP-Kit on Ventana Bench-
mark.
PanMelanoma Cocktail (Biocare Medical, clone HMB-45+M2-
7C10+M2-9E3, dilution 1:50, pre-treatment: CC1-buffer for
20 min/98uC), detection was performed with Ultra View-AP Kit
(substrate: New-fuchsin) on Ventana Benchmark. Anti-Glut-1
(Chemicon, AB1341, dilution 1:1000, pre-treatment: CC1-buffer
for 20 min/98uC) and anti-MECA32 (PharMingen, #553849,
dilution 1:100, pre-treatment: Leica buffer H2 for 40 min/98uC)
detection were performed with Refine-HRP-Kit on BondMax
from Leica. Collagen IV (BMA Biomedicals AG, dilution 1:30,
pre-treatment: Ventana protease 1/12 min.) Detection was
performed with iVIEW-HRP-Kit on Ventana Discovery, using
secondary antibody Donkey anti-Rabbit biotinylated, Jackson 711-
065-152, diluted 1:80). Substrate for all HRP-Kits was Diamino-
benzidin (DAB). Counterstain was done with Hematoxylin from
the Immunostaining-Kits
Human tumor cell isolation and xenotransplantation
Studies described in this publication were performed according
to Swiss Animal Welfare laws and specifically as described in
animal licenses No. 77/2008 (Int. 3816) issued and approved by
the Cantonal Veterinary Office (official state office), of the Canton
of Zurich (permission submitted in the supplement). The approval
was signed by Mrs. Dr. Simone Gilg, scientific board deputy and
responsible for the review board of the Cantonal Veterinary
Office, of the Canton of Zurich. The approval ID/permit number
is 2008077.
The melanoma cell line (M010308) and the melanoma cell lines
used for chromosome 17/HER-2 probe were obtained from
consenting patients, according to the guidelines of the University
Hospital of Zurich. The permission to produce cell cultures from
fresh tumor tissue was given from the cantonal ethic commission in
Zu ¨rich. The consent statement was written (EK-No. 647, see
attached permission in the supplement). Melanoma cell lines used
for the chromosome 17/HER-2 probe are additionally described
in more detail in a recent publication [28]. HEK293 cells were
bought from GenHunter (www.genhunter.com; cat. number
Q401).
In order to demonstrate mosaic microvessels 2 xenotransplan-
tations with male/female constellation were established as follows:
a male melanoma cell culture (M010308) established 4 years ago
which went through at least 20 passages, which was frozen and re
thawed several times and finally was used for xenotransplantations
in female athymic nude mice. The cell line (M010308) was proven
to be negative for CD31 and CD34 by immunohistochemistry
(data not shown). From the melanoma culture, a total of 3610E6
cells were injected into both flanks of 8-week-old female athymic
nude mice. Mice were kept in individually ventilated cages for a
maximum of 75 days postinjection. Tumour volume was measured
using vernier calipers once every 1 or 2 days during the linear
growth phase. If at least one xenograft tumor reached 1 cm
3, the
mouse was sacrificed and the tumors were investigated with the y-
chromosome probe.
In addition using melanoma patients cell line [28] 4
xenotransplantations were established in the following way:
Immediately after surgical resection, solid metastatic lesions were
dissociated into single-cell suspensions using HBSS (without Ca
2+
and Mg
2+, Invitrogen) containing Collagenase III (1 mg/ml,
Worthington Bioch.) and Dispase (0.5 mg/ml, Roche). Incubation
at 37uC for 1 h with concurrent mincing allowed complete
digestion. The resulting cell suspension was filtered through 40 mm
nylon mesh and single cells were harvested. Afterwards the cells
were cultured in neuro-sphere conditions and passed 8 times. Due
to the limited amount of cells, patient tumor xenografts were
established by subcutaneous injection of dissociated bulk melano-
ma cells into nude BALBc/Swiss mice. Resulting patient tumor
xenografts were harvested, dissociated as described above.
Thereafter tumor cells were labelled with the neuroectodermal
marker p75, sorted by FACS and again injected into nude athymic
mice. The resulting tumors were investigated by chromogenic in
situ hybridization for the human HER-2 probe localized on
chromosome 17.
Fluorescence In situ hybridization (FISH) combined with
Fluorescence Immunphenotyping and Interphase
Cytogenetics (FICTION)
FICTION simultaneously enables to perform cytogenetic
investigation by FISH and immunophenotyping by fluorescence
marked immunohistochemistry (FICITION=fluorescence immu-
nophenotyping, and interphase cytogenetics as a tool for the
investigation of neoplasms)
Human chromosome 17/HER2 probe and MECA32
Immunohistochemistry on BondMax (Leica), detection of
primary Rat anti-Mouse panendothelial MECA32 (Pharmingen
Becton/Dickinson, dilution 1:100) with Refine HRP-Kit (Leica)
and Link-antibody Rabbit anti-Rat (Jackson, dilution: 1:150).
Antigen-Retrieval: HIER buffer2 (Leica) for 40 min, Chromogen
DAB, without counterstain. Followed by FISH with HER-2- and
centromeric probe for chromosome 17 (ABBOTT Molecular),
according to the manufacturers guidelines. Counterstain with
DAPI.
Human X/Y-Chromosome/CD31 (FICTION)
FISH analysis for CEP X (DXZ1) Spectrum Green/CEP Y
(DYZ3) Spectrum Orange Probe (ABBOTT Molecular) was
performed according to the manufacturers’ protocol. FISH
procedure was followed by the detection of human endothelial
cells: Mouse anti-human CD31 (DAKO, dilution 1:10) was
coupled with a fluorescence labeled secondary antibody: Goat
anti-mouse Alexa488 (Molecular Probes, dilution 1:100), counter-
stain with DAPI (Incubation at room-temperature for 30 min
each).
A cell was defined as human-derived as follows: on confocal
microscopy, the nucleus had to present typical endothelial
morphology, being positive for the Y-probe, and the CD31
positive cytoplasm had to be fully discernible.
Human ALU-repeat probe and CD31
All procedures were done on BondMax (Leica) with Kits and
solutions from Leica according to the manufacturer’s guidelines.
Epitope-retrieval was performed with Bond heat-pre-treatment-
buffer 2 for 20 min. at 100uC. Immunohistochemistry was done
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Bond
TM Polymer Refine Red Detection (Leica) without nuclear
staining. Endogenous biotin was subsequently blocked with
Avidin-Biotin-Blocking Kit (CellMarque, Cat. 928B-02) and in-
situ-hybridization was performed using enzyme pretreatment
(Leica, Enzyme) followed by the DNA-hybridization with a
biotinylated human ALU-repeat DNA_positive-control-probe
(Leica, Cat. PB0682) according to the manufacturer’s protocol.
Bound probes were detected with a rabbit anti-biotin antibody
(Bethyl Cat. A150-109A, dilution 1:1500) and with donkey anti-
rabbit Dylight488 (Jackson, Cat. 711-486-152, dilution 1:1000).
Slides were mounted with Vectashield Hard-Set Mounting
Medium with DAPI (Vector Laboratories, H-1500). The CD31-
specific fast red color precipitate was detected in the red and the
human DNA-specific ALU-repeat in situ hybridization in the
green fluorescence channel, respectively.
GFP (Green fluorescent protein)
Immunohistochemistry on BondMax (Leica) with Refine-DAB-
Kit including counterstain. Epitop-retrieval with Bond Heat-pre-
treatment-buffer 2 for 30 min. Primary antibody Chicken anti-
GFP (Abcam ab13970, 1:2000), secondary antibody Rabbit anti-
Chicken Y (Abcam ab6753, 1:300).
Fluorescence Imaging
Confocal image acquisition was done using sequential mode on
a Leica TCS SP5 confocal laser scanning microscope (Mannheim,
Germany). Co-localization studies were conducted using IMARIS
software (Bitplane, Zurich, Switzerland).
Melanoma cell infection with GFP-labelled lentivirus
Freshly isolated melanoma cells were injected into nude athymic
mice. Patient tumour xenografts were harvested and cells
dissociated as described above. Some of those cells were cultured
in neuro-sphere condition and passed 8 times. At the 8th passage
the cells were infected with a GFP driving virus.
GFP-expressing lentivirus was produced by transient four-
plasmids cotransfection into HEK 293 [29] with VSV-pseudo-
typed third-generation lentiviral vectors (LV) by using calcium
phosphate method. Supernatants were collected 48 hours after
transfection, filtered through a 0.22 mm membrane [30] and
transferred to target cells. Resulting GFP-tagged tumor cells were
checked by FACS and subcutaneously injected as described above.
Statistical analyses
CD34 and D2–40 expressions are presented as median with
range and compared between different patient groups using the
Mann-Whitney and the Krustal-Wallis test. Glut-1 expression was
compared using Fisher’s exact test. Differences between CD34 and
D2–40 expressions were compared using the Wilcoxon signed
rank test. P-values below 0.05 were considered as significant. SPSS
16.0 for Windows (SPSS Inc., Chicago, IL) was used for statistical
analyses.
Results
Primary melanomas show a higher lymphatic vessel
density than melanoma metastases
We investigated 127 melanoma metastases (21 lymph nodes and
106 other sites) and 49 primary melanomas for vascularisation.
The number of vessels was counted per core. There were
significantly more D2–40 positive lymphatic vessels in primary
melanoma than in melanoma metastases (p,0.0001; Figure 1A).
Only 15 of 127 (12%) metastases had lymphatic vessels whereas 39
of 49 (80%) primary melanomas were positive for lymphatic
vessels. Metastases had a mean of 0.6 lymphatic vessels per core
(median 0; range 0–15) in contrast to primary tumors with a mean
of four lymphatic vessels per core (median 3; range 0–15; Table 1).
Analyzing a separate collection of 48 complete paraffin-embedded
metastases (35 lymph node and 13 organ metastases) confirmed
negativity for lymphatic vessels. 18 of 48 (38%) metastases were
completely negative for lymphatic vessels, while 23 (48%) showed
foci of dilated lymphatic vessels at the interphase to normal organ
parenchyma. All but three of these were lymph node metastases
(Figures 1B, C). Only seven (14%) had few lymphatic foci within
the metastatic body. However, normal skin 0,5 cm adjacent to the
primary melanoma showed an average of 8 vessels per mm
2 which
is congruent with the literature [31]. In contrast lymph node tissue
0,5 cm adjacent to the metastases showed no lymphatic vessels.
However, in all 48 cases blood neovascularization was prominent.
The lymph node metastases comprised 20 macro- and 15 micro-
metastases (,2 mm). Congruent with Folkman’s findings [32] we
found neither lymphatic nor blood-micro-vessels in micro-
metastases.
There were significantly more blood than lymphatic microvessels
in primary melanomas (p,0.0001) as well as in metastases
(p,0.0001). In addition primary melanomas had significantly more
blood vessels than metastases (p=0.012). Primary melanomas had
an average of 20 blood vessels per core (median 19; range 1–60) and
metastases had an average of 15 blood vessels (median 11; range 0–
69) per core (Table 1). There was no statistically significant
difference in vessel density or composition between lymph node and
organ metastases. Interestingly, there was a virtual homogenous
distribution of blood neovascularization over cross section of
metastases. In large metastases there was no difference between
central and peripheral regions. We could not find blood vessel
concentrations at the interface with normal lymphatic tissue as
found for lymphatic vessels (Figure 1D). Glut-1 expression in
melanoma cells is an indicator of a hypoxic environment. We
analyzed Glut-1 expression semi quantitatively and differentiated
between Glut-1 expression in less or more than 50% of melanoma
cells per core. There was a significant difference between primary
melanoma and metastases (p=0.002). 45 of 127 (35%) melanoma
metastases showed Glut-1 expression in more than half of the cells
whereas this was true for only 6 of 49 (12%) primary melanomas. A
significant inverse correlation between blood vessel number and
Glut-1 expression in melanoma (p=0.0002) indicates the function-
ality of blood neovascularization.
Melanoma cells participate in neovascularization during
tumorigenesis
We investigated six xenografts of human melanoma cell lines
labelled with p75 and sorted by FACS as described in material and
methods for MECA32, a marker specific for mouse vessel
endothelia. There was significant neovascularization within the
tumor (Figures 2A, B). Most endothelial cells surrounding
microvessels were MECA32 positive, indicating their mouse
origin. However, fluorescence double-labelling showed that some
were negative for MECA32 and positive for human chromosome
17 and HER-2, indicating their melanoma origin (Figure 2C). As
they have the same staining properties and a similar endothelial
morphology as melanoma cells of VMs we introduced for
melanoma cells in VMs as well as for melanoma cells contributing
to capillaries the term endothelial-like cell. For quantifying the
percentage of endothelial-like tumor derived cells contributing to
capillaries, chromogenic in situ hybridization for HER-2 gene
probe and centromeric probe for chromosome 17 was used
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tissue were used as a negative internal control (Figure 2E). We
identified 6% of all capillary lining cells as endothelial-like cells.
Endothelial-like cells of VMs are not included in this account. In
addition, tumor cell contribution to neovascularization was also
confirmed by combined in situ- and immunofluorescence labelling
in the mouse model displaying double-positivity of endothelial-like
cells for the vessel marker CD31 and the human Y-chromosome
(Figure 2G) as well as for CD31 and the human-DNA specific
ALU-repeat sequences (Figure 3A–D). Mouse vessels of adjacent
tissues served as internal negative controls (2F).
Table 2 overviews all experiments confirming the melanoma
cells contribution to neovascularisation
Vascular mimicries in human metastases and xenograft
tumors
Vascular mimicries (VM) were observed in both human
metastases (Figures 1E, F, G, 4A, B) and mouse xenografts
(Figure 2B, H). Melanoma cells contributing to VM were
embedded in a PAS (1F) and collagen IV (1G) positive
extracellular matrix, were small with endothelial-like cell mor-
phology and highly condensed nuclei (Figures 1E, F, G). Most of
these cells were negative for PanMelanoma (HMB-45 and MART-
1). However, some contained melanin (Masson Fontana positive)
or were positive for PanMelanoma (Figures 4A, B) indicating their
melanocytic origin. Most importantly, VM in xenografts were
positive for the chromosome 17 and HER-2 probe (Figure 2H)
and GFP fluorescence labelling, which proofed their melanoma
derivation (Figure 2 I, J).
In contrast to their endothelial-like morphology, they were
negative for CD31, CD34 and D2–40. In xenografts tumor cell
VM were associated with MECA32-positive mouse derived
microvessels (Figure 2B) whereas in human melanoma metastases
they associated and connected with CD34-positive blood vessels
(Figure 1E).
Discussion
The establishment of metastases is a complex process, which
includes angiogenic development. Several studies have shown that
increased lymphatic density in primary melanomas is associated
with a higher incidence of regional lymph node metastases [5,33].
Table 1. Blood and lymphatic vessels per TMA core
(0,28 mm
2) in primary and metastatic melanoma.
Primary
melanomas
Metastases of
melanoma P-value
Sample number 49 127
Lymphatic vessels (D2–40) 4640 . 6 62 ,0.0001
Blood vessels (CD34) 20614 15614 0.01
6 Mean 6 SD.
doi:10.1371/journal.pone.0033571.t001
Figure 1. Human melanoma lymph node metastases (entirely embedded). (A) Box plot comparison of lymphatic vessels (number of D2–40
positive vessels per core) in primary versus metastatic melanoma. * One case, * two cases. (B) Absence of D2–40 staining within metastatic tissue
showing no lymphatic vessels (630). (C) D2–40 positivity shows dilated lymphatic vessels present at the tumor/lymphatic parenchyma interface
(arrow, 6150). (D) CD34 staining shows important blood micro-neovascularisation within metastases. (650). (E) CD34-positive blood microvessels
(arrowhead) associated with CD34–negative cells showing vascular mimicry (arrow,6400). (F) and (G) Cells of vascular mimicries embedded in a PAS
(F) and collagen IV (G) positive laminina (arrow, 6320)).
doi:10.1371/journal.pone.0033571.g001
Angiogenesis in Melanoma
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human cancers and these are mostly restricted to breast cancer
[6,34,35,36]. In our study, we examined 175 melanoma
metastases for lymphatic and blood vessel formation using
immunohistochemistry. We found significantly more lymphatic
vasculature in primary than in metastatic melanomas (p,0.0001).
In contrast to the lymphangiogenesis seen in primary lesions,
there were few lymphatic vessels observed within lymph node and
organ metastases. The few lymphatic vessels identified were mostly
found in foci at the metastatic lymph node interphase, or in the
lymph node parenchyma close to metastases, and these were often
angiectatic (Figures 1B, C). Our histopathological observations
correspond well with van den Eynden’s reports on breast cancer
[34]. In melanoma metastases lymphatic foci have also been
reported, however no information on their in situ distribution was
provided [6].
However, we observed a significant anatomical difference in
lymphatic density with a mean of 8 lymphatic vessels in normal
skin 0,5 cm adjacent to the primary melanoma and absence in
lymph node tissue 0,5 cm adjacent to the metastases. However,
despite those anatomical differences, there still remained a
significant difference in lymphatic vascularization between prima-
ry melanoma and adjacent normal tissue indicating the lymphatic
induction potential of primary melanoma, which was almost
absent in metastases. Lymphatic induction in primary melanoma
and its prognostic relevance is well documented. In addition
lymphatic induction is also a part of regression in primary
melanoma [31,33].
Melanoma metastases presented a highly complex neovascular-
ization with immunoreactivity for CD34 and negativity for D2–40.
Furthermore, the highly significant inverse correlation between
expression of Glut-1 (implying local hypoxia) and the presence of
micro vessels suggests that hypoxia is a major driver (p,0.0001;
Figure 1A). Interestingly there was a homogenous distribution of
micro blood vessels over whole metastases. In terms of their
structure, we observed that these tumor vessels are abnormal as
their walls have numerous ‘openings’. Ultrastructure studies of
tumor vessels have shown endothelial fenestrae, transcellular holes,
widened interendothelial junctions, and discontinuous or absent
basement membranes. Such defects are known to make tumor
vessels leaky [37] [38]. Increasing neovascularization with leaky
vessels may contribute to hematogenous spread. The vascular
Figure 2. Melanoma xenograft tissues. (A) Mouse vessel-specific MECA32 staining shows micro-neovascularisation within melanoma xenografts
(arrowhead, 6100) and positive vessels of the adjacent soft tissue (arrow). (B) Vascular mimicries negative for MECA32 (arrow) associated with and
connecting MECA32-positive vessels (arrowhead, 6175). (C) Interphase FISH for human chromosome 17 and HER-2 combined with
immunofluorescence staining for the mouse-specific vessel marker MECA32: Tumor capillaries with endothelial cells positive for MECA32 (yellow)
and negative for HER-2 (arrow) as well as endothelial-like cell with negativity for MECA32 and positivity for human chromosome 17 and HER-2
(arrowhead, green; 6500). (D) and (G) Melanoma tumor cell-derived endothelial-like cells: (D) Capillary endothelial-like cell positive for human
chromosome 17 and HER-2 (arrow) and positive internal control of tumor cells (arrowhead,6500. (E) and (F) Negative internal controls of slide D and
G. Melanoma xenograft adjacent soft tissue with mouse capillaries and fibroblasts negative for human chromosome 17_HER-2 probe (E, 6500) and
negative for FISH y probe and CD31 (F, 6700). (G) Interphase FISH for human y-probe combined with immunofluorescence staining for the human-
specific vessel marker CD31: Vessel endothelial-like cell positive for the Y chromosome (red) and CD31 (arrowhead, green; 61000). (H) Vascular
mimicries (arrow): Endothelial-like cells positive for human chromosome 17 and HER-2 (arrowhead, 6300). (K) and (L) Green fluorescent protein
labelled melanoma cell lines: Melanoma cells (arrowhead, green) and endothelial cells (arrow) contributing to complex branching neo-vascularisation.
(K 6200; L 6500).
doi:10.1371/journal.pone.0033571.g002
Figure 3. FICTION for human ALU-repeat probe and CD31 in melanoma xenograft tissue. Melanoma derived endothelial-like cells of
tumor capillaries with nuclear positivity for the human-DNA specific ALU-repeat sequences (A, D arrow, green, 6700) and cytoplasmic positivity for
CD31 (A, B, arrow, red,6700). Mouse derived endothelial cells with negativity for the human-DNA specific ALU-repeat sequences (D arrow head) and
cytoplasmic positivity for CD31 (B arrow head, red). Internal control with nuclear positivity for the human-DNA specific ALU-repeat sequences A, D)
and negativity for CD31 in melanoma cells (A, B, asterix).
doi:10.1371/journal.pone.0033571.g003
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tumor cells is a major stimulator of angiogenesis [39]. Considering
the tremendous neovascularisation of melanoma metastases, it is
not surprising that inhibition of the VEGF signalling pathway has
shown promising therapeutic benefits. Unfortunately, adaptive
tumor responses are often observed, indicating the need for further
understanding of VEGF regulation. Recently, a novel G protein-
coupled receptor, GPR56, which inhibits VEGF production from
the melanoma cell lines [40], as well as heparanase, which induces
VEGF, were reported as possible tumor targets for influencing
VGEF expression [41]. In contrast, one could speculate that anti-
angiogenic therapies result in hypoxic condition and therefore
benefit the growing of VM which represent the aggressive invasive
form of melanoma.
Similar blood neovascularization was found in xenografts of
human melanoma cell cultures. These vessels were mostly positive
for the mouse-specific vessel marker MECA32. However, about
6% of endothelial-like cells were negative for this marker. We
propose that these MECA32-negative cells are tumor-derived
because they are positive for the human chromosome 17 and
HER-2 (Figure 2 D), are positive for the Y-chromosome and
CD31 in xenotransplantations of male melanoma patient cell lines
in female mice (Figure 2 G), are positive for the ALU-repeat and
CD31 (Figure 3 A–D) and they express transfected green
fluorescent protein (Figure 2 I, J). Taken together, we conclude
that melanoma cells acquire vascular endothelial-like morphology
and are incorporated in capillaries and thus actively contribute to
the establishment of neovascularization [42]. These features are in
congruence with findings from the laboratory of Mary Hendrix
[23]. This group injected aggressive melanoma cells containing a
fluorescent label into the ischemic hind limbs of nude mice, which
were re-perfused five days later. Histological cross-sections of
newly formed vasculature in re-perfused limbs showed human
melanoma cells adjacent to and overlapping with mouse
endothelial cells in a linear arrangement.
Cells involved in VM express genes associated with embryonic
stem cells including those associated with primordial vascular
development [14,19,20,21,43]. In a recent study, we have
provided evidence for molecular plasticity in melanoma switching
between proliferative and invasive phenotypes [13]. Culturing
invasive phenotype melanoma cells on matrigel causes them to
adopt VM morphologies. In addition, Hess et al have shown that
epithelial cell kinase is a critical molecular determinant for VM in
aggressive melanoma cells. Inhibition of tyrosine phosphorylation
abrogates the ability of the aggressive melanoma cells to form VMs
[21]. Therefore we postulate that VM tumor cells represent the
invasive phenotype in vivo. Very recently, two independent groups
revealed that a proportion of the endothelial cells of blood vessels
in glioblastoma originate from the tumour cell population as
proven by tumor specific genetic alterations [25,26].
Approximately one million tumor cells are shed per g of tumor
per day [44]. Chang and Maniotis have shown in colon cancer
and melanoma the functional activity of VM and their implication
for tumor shedding [14,22]. Our results indicate that the
melanoma lymph node metastases with tremendous neovascular-
ization, VM and leaky vessels are a direct contributor to
Table 2. Overview of melanoma xenograft experiments used for illustrating melanoma cells participation in neovascularisation.
Method Result Shown in figure
Interphase FISH for human chromosome 17 and HER-2
combined with immunofluorescence staining for the
mouse-specific vessel marker MECA32:
Capillary lining cells (endothelial-like cells)
negative for MECA32 and positive for human
chromosome 17 and HER-2
2C
Chromogenic in situ hybridization for human centromeric
chromosome 17 and HER-2 gene probe
6% of all capillary lining cells
(endothelial-like cells) are positive
2D
Interphase FISH for human y-probe combined with
immunofluorescence staining for the human-specific
vessel marker CD31
Endothelial-like cells positive for the Y
chromosome and CD31
2G
Interphase FISH for the human DNA specific ALU-repeat
combined with immunofluorescence staining for CD31
Endothelial-like cells positive for the human-DNA
specific ALU-repeat sequences and CD31
3A–D
doi:10.1371/journal.pone.0033571.t002
Figure 4. Human melanoma lymph node metastases (entirely embedded). (A) and (B) Vascular mimicries (arrow): (A) Melanoma cells with
endothelial-like morphology, condensed nuclei, minimal Masson Fontana positive (inset) pigmentation (H&E, 6500), (B) mostly negative for
PanMelanoma (red) (6150).
doi:10.1371/journal.pone.0033571.g004
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directly contributing to the capillary network is interesting
concerning tumor cell plasticity and tumor cell niche aspects.
Looking at the high number of tumor shedding, they at first seem
irrelevant. However, they have a remarkable plastic capacity and
by lack of melanocytic differentiation, antigens escape normal
immune surveillance. Therefore, their influence in metastatic
disease or tumor relapse should not be underestimated.
In summary, we found a complex neovascularization consisting
of VMs and leaky blood micro vessels in human melanoma
biopsies and melanoma xenografts. In addition, melanoma cells
contributed to tumor capillaries.
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